CymaBay Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 41.9 million compared to USD 26.63 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.3 a year ago.